title: Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis.
abstract: Human papillomavirus (HPV) exists as more than 100 genotypes. It is not well-established whether the different HPV types interfere with infection or pathogenesis by each other. Possible interactions in cervical carcinogenesis between infection with the most common HPV types (6, 11, 16, 18 and 33) were studied in a seroepidemiological case- control study of 218 women with primary untreated cervical cancer and 219 healthy age-matched control women. As previously shown, HPV-16 seropositivity was associated with cervical cancer risk [odds ratio (OR), 2.39], but HPV-16 was not associated with cervical cancer risk among HPV-6 seropositive women (OR, 1.0). The relative excess risk due to interaction between HPV-6 and -16 was -2. 35 (95% confidence interval, -0.04 to -4.65), indicating significant antagonism. The results suggest that infection with HPV-6 may interfere with HPV-16-associated cervical carcinogenesis.
authors.affiliation: Microbiology and Tumor Biology Center, Karolinska Institute, Box 280, S-171 77 Stockholm, Sweden1.
authors.forename: Ilvars
authors.initials: I
authors.lastname: Silins
authors.affiliation: Microbiology and Tumor Biology Center, Karolinska Institute, Box 280, S-171 77 Stockholm, Sweden1.
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Gynaecologic Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden2.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Åvall-Lundqvist
authors.affiliation: Department of Gynaecologic Oncology, Radiumhemmet, Karolinska Hospital, Stockholm, Sweden2.
authors.forename: Bo
authors.initials: B
authors.lastname: Frankendal
authors.affiliation: University of Latvia, Riga, Latvia3.
authors.forename: Uldis
authors.initials: U
authors.lastname: Vikmanis
authors.affiliation: Department of Medical Microbiology, University of Mainz, Mainz, Germany4.
authors.forename: Martin
authors.initials: M
authors.lastname: Sapp
authors.affiliation: Laboratory of Cellular Oncology, The National Cancer Institute, Bethesda, MD, USA5.
authors.forename: John T
authors.initials: JT
authors.lastname: Schiller
authors.affiliation: Department of Infectious Disease Epidemiology, National Public Health Institute, Helsinki, Finland6.|Microbiology and Tumor Biology Center, Karolinska Institute, Box 280, S-171 77 Stockholm, Sweden1.
authors.forename: Joakim
authors.initials: J
authors.lastname: Dillner
mesh_terms: D000914:Antibodies, Viral / Q000097:blood; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control*; D016036:Seroepidemiologic Studies; D014412:Tumor Virus Infections / Q000517:prevention & control*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology
chemical_list: D000914:Antibodies, Viral